Close Menu

NEW YORK (GenomeWeb) – Biocartis said yesterday that it has signed a development agreement with Genomic Health to develop an in vitro diagnostic version of the Oncotype DX Genomic Prostate Score (GPS) Test.

The agreement expands on a previous partnership to develop an IVD version of Genomic Health's Oncotype DX Breast Recurrence Score test on Biocarts' Idylla platform.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.